Centre variation in mortality following post-hospitalization acute kidney injury: analysis of a large national cohort.


Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
19 10 2022
Historique:
received: 25 11 2020
pubmed: 14 12 2021
medline: 25 10 2022
entrez: 13 12 2021
Statut: ppublish

Résumé

Routine monitoring of outcomes for patients with acute kidney injury (AKI) is important to drive ongoing quality improvement in patient care. In this study we describe the development of a case mix-adjusted 30-day mortality indicator for patients with post-hospitalization AKI (PH-AKI) across England to facilitate identification of any unwarranted centre variation in outcomes. We utilized a routinely collected national dataset of biochemically detected AKI cases linked with national hospitals administrative and mortality data. A total of 250 504 PH-AKI episodes were studied across 103 National Health Service hospital trusts between January 2017 and December 2018. Standardized mortality ratios (SMRs) were calculated for each trust using logistic regression, adjusting for age, sex, primary diagnosis, comorbidity score, AKI severity, month of AKI and admission method. The mean 30-day mortality rate was high, at 28.6%. SMRs for 23/103 trusts were classed as outliers, 12 above and 11 below the 95% confidence limits. Patients with PH-AKI had mortality rates >5 times higher than the overall hospitalized population in 90/136 diagnosis groups and >10 times higher in 60/136 groups. Presentation at trusts with a co-located specialist nephrology service was associated with a lower mortality risk, as was South Asian or Black ethnicity. Deprivation, however, was associated with higher mortality. This is the largest multicentre analysis of mortality for patients with biochemically ascertained PH-AKI to date, demonstrating once again the considerable risk associated with developing even mild elevations in serum creatinine. Mortality rates varied considerably across centres and those identified as outliers will now need to carefully interrogate local care pathways to understand and address the reasons for this, with national policy required to tackle the identified health disparities.

Sections du résumé

BACKGROUND
Routine monitoring of outcomes for patients with acute kidney injury (AKI) is important to drive ongoing quality improvement in patient care. In this study we describe the development of a case mix-adjusted 30-day mortality indicator for patients with post-hospitalization AKI (PH-AKI) across England to facilitate identification of any unwarranted centre variation in outcomes.
METHODS
We utilized a routinely collected national dataset of biochemically detected AKI cases linked with national hospitals administrative and mortality data. A total of 250 504 PH-AKI episodes were studied across 103 National Health Service hospital trusts between January 2017 and December 2018. Standardized mortality ratios (SMRs) were calculated for each trust using logistic regression, adjusting for age, sex, primary diagnosis, comorbidity score, AKI severity, month of AKI and admission method.
RESULTS
The mean 30-day mortality rate was high, at 28.6%. SMRs for 23/103 trusts were classed as outliers, 12 above and 11 below the 95% confidence limits. Patients with PH-AKI had mortality rates >5 times higher than the overall hospitalized population in 90/136 diagnosis groups and >10 times higher in 60/136 groups. Presentation at trusts with a co-located specialist nephrology service was associated with a lower mortality risk, as was South Asian or Black ethnicity. Deprivation, however, was associated with higher mortality.
CONCLUSIONS
This is the largest multicentre analysis of mortality for patients with biochemically ascertained PH-AKI to date, demonstrating once again the considerable risk associated with developing even mild elevations in serum creatinine. Mortality rates varied considerably across centres and those identified as outliers will now need to carefully interrogate local care pathways to understand and address the reasons for this, with national policy required to tackle the identified health disparities.

Identifiants

pubmed: 34902021
pii: 6460506
doi: 10.1093/ndt/gfab348
doi:

Substances chimiques

Creatinine AYI8EX34EU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2201-2213

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.

Auteurs

Javeria Peracha (J)

UK Renal Registry, The UK Kidney Association, Bristol, UK.
Department of Renal Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK.

David Pitcher (D)

UK Renal Registry, The UK Kidney Association, Bristol, UK.

Shalini Santhakumaran (S)

UK Renal Registry, The UK Kidney Association, Bristol, UK.

Retha Steenkamp (R)

UK Renal Registry, The UK Kidney Association, Bristol, UK.

James Fotheringham (J)

School of Health and Related Research, University of Sheffield, Sheffield UK.
Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Jamie Day (J)

Getting it Right First Time Programme, NHS England and NHS Improvement, London, UK.

James F Medcalf (JF)

UK Renal Registry, The UK Kidney Association, Bristol, UK.
John Walls Renal Unit, University Hospitals Leicester NHS Trust, Leicester, UK.

Dorothea Nitsch (D)

UK Renal Registry, The UK Kidney Association, Bristol, UK.
Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK.
Department of Nephrology, University College London Hospitals NHS Trust, London, UK.

Graham W Lipkin (GW)

Department of Renal Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK.

William S McKane (WS)

Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH